Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome

Background A previous subgroup analysisof a 12-week, double- blind studydemonstrated that losartansignificantly lowered proteinuriaversus placebo and amlodipineand was well tolerated in children (1–17 years old) with proteinuriasecondary to Alport syndrome. The present subgroup analysisof the open-label, extension phase of this study assessed the long-term efficacy and tolerability of losartanversus enalapril.